These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 36446639)
1. Ferritin Nanocaged Doxorubicin Potentiates Chemo-Immunotherapy against Hepatocellular Carcinoma via Immunogenic Cell Death. Chen Y; Zeng L; Zhu H; Wu Q; Liu R; Liang Q; Chen B; Dai H; Tang K; Liao C; Huang Y; Yan X; Fan K; Du JZ; Lin R; Wang J Small Methods; 2023 May; 7(5):e2201086. PubMed ID: 36446639 [TBL] [Abstract][Full Text] [Related]
2. Ferritin-Based Nanocomposite Hydrogel Promotes Tumor Penetration and Enhances Cancer Chemoimmunotherapy. Liu R; Liang Q; Luo JQ; Li YX; Zhang X; Fan K; Du JZ Adv Sci (Weinh); 2024 Jan; 11(3):e2305217. PubMed ID: 38029345 [TBL] [Abstract][Full Text] [Related]
3. EGFR-targeted multifunctional polymersomal doxorubicin induces selective and potent suppression of orthotopic human liver cancer in vivo. Fang Y; Yang W; Cheng L; Meng F; Zhang J; Zhong Z Acta Biomater; 2017 Dec; 64():323-333. PubMed ID: 29030307 [TBL] [Abstract][Full Text] [Related]
4. H-ferritin-nanocaged doxorubicin nanoparticles specifically target and kill tumors with a single-dose injection. Liang M; Fan K; Zhou M; Duan D; Zheng J; Yang D; Feng J; Yan X Proc Natl Acad Sci U S A; 2014 Oct; 111(41):14900-5. PubMed ID: 25267615 [TBL] [Abstract][Full Text] [Related]
5. Low-toxicity transferrin-guided polymersomal doxorubicin for potent chemotherapy of orthotopic hepatocellular carcinoma in vivo. Wei Y; Gu X; Cheng L; Meng F; Storm G; Zhong Z Acta Biomater; 2019 Jul; 92():196-204. PubMed ID: 31102765 [TBL] [Abstract][Full Text] [Related]
6. High hydrostatic pressure encapsulation of doxorubicin in ferritin nanocages with enhanced efficiency. Wang Q; Zhang C; Liu L; Li Z; Guo F; Li X; Luo J; Zhao D; Liu Y; Su Z J Biotechnol; 2017 Jul; 254():34-42. PubMed ID: 28591619 [TBL] [Abstract][Full Text] [Related]
7. Ferritin nanocages for early theranostics of tumors via inflammation-enhanced active targeting. Jiang B; Jia X; Ji T; Zhou M; He J; Wang K; Tian J; Yan X; Fan K Sci China Life Sci; 2022 Feb; 65(2):328-340. PubMed ID: 34482518 [TBL] [Abstract][Full Text] [Related]
8. Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway. Lu J; Liu X; Liao YP; Wang X; Ahmed A; Jiang W; Ji Y; Meng H; Nel AE ACS Nano; 2018 Nov; 12(11):11041-11061. PubMed ID: 30481959 [TBL] [Abstract][Full Text] [Related]
9. Hydrazide-manganese coordinated multifunctional nanoplatform for potentiating immunotherapy in hepatocellular carcinoma. Hou G; Qian J; Guo M; Xu W; Wang J; Wang Y; Suo A J Colloid Interface Sci; 2022 Dec; 628(Pt B):968-983. PubMed ID: 36037718 [TBL] [Abstract][Full Text] [Related]
10. Targeted Nanobubbles of PD-L1 mAb Combined with Doxorubicin as a Synergistic Tumor Repressor in Hepatocarcinoma. Chen Y; Luo X; Liu Y; Zou Y; Yang S; Liu C; Zhao Y Int J Nanomedicine; 2022; 17():3989-4008. PubMed ID: 36105615 [TBL] [Abstract][Full Text] [Related]
12. Bacterial magnetosomes loaded with doxorubicin and transferrin improve targeted therapy of hepatocellular carcinoma. Wang J; Geng Y; Zhang Y; Wang X; Liu J; Basit A; Miao T; Liu W; Jiang W Nanotheranostics; 2019; 3(3):284-298. PubMed ID: 31423412 [TBL] [Abstract][Full Text] [Related]
13. Doxorubicin-Near infrared dye conjugate induces immunogenic cell death to enhance cancer immunotherapy. Jin C; Wang Y; Li Y; Li J; Zhou S; Yu J; Wang Z; Yu Y; Zhang H; Wang D; He Z; Wang Y Int J Pharm; 2021 Sep; 607():121027. PubMed ID: 34418473 [TBL] [Abstract][Full Text] [Related]
14. Cucurbitacin IIa promotes the immunogenic cell death‑inducing effect of doxorubicin and modulates immune microenvironment in liver cancer. Li S; Wang S; Zhang A; Luo L; Song J; Wei G; Fang Z Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38391053 [TBL] [Abstract][Full Text] [Related]
15. Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence. Zhang F; Jia Y; Zheng X; Shao D; Zhao Y; Wang Z; Dawulieti J; Liu W; Sun M; Sun W; Pan Y; Cui L; Wang Y; He K; Zhang M; Li J; Dong WF; Chen L Acta Biomater; 2019 Dec; 100():352-364. PubMed ID: 31563690 [TBL] [Abstract][Full Text] [Related]
16. A Sodium Alginate-Based Multifunctional Nanoplatform for Synergistic Chemo-Immunotherapy of Hepatocellular Carcinoma. Huang C; Xie T; Liu Y; Yan S; OuYang F; Zhang H; Lei L; He D; Wei H; Yu CY Adv Mater; 2023 Aug; 35(33):e2301352. PubMed ID: 37216573 [TBL] [Abstract][Full Text] [Related]
17. Isoginkgetin synergizes with doxorubicin for robust co-delivery to induce autophagic cell death in hepatocellular carcinoma. Wang Y; Yi Y; Yao J; Wan H; Yu M; Ge L; Zeng X; Wu M; Mei L Acta Biomater; 2022 Nov; 153():518-528. PubMed ID: 36152910 [TBL] [Abstract][Full Text] [Related]
18. Co-delivery of glycyrrhizin and doxorubicin by alginate nanogel particles attenuates the activation of macrophage and enhances the therapeutic efficacy for hepatocellular carcinoma. Wang QS; Gao LN; Zhu XN; Zhang Y; Zhang CN; Xu D; Cui YL Theranostics; 2019; 9(21):6239-6255. PubMed ID: 31534548 [TBL] [Abstract][Full Text] [Related]
19. Extending Half Life of H-Ferritin Nanoparticle by Fusing Albumin Binding Domain for Doxorubicin Encapsulation. Wang C; Zhang C; Li Z; Yin S; Wang Q; Guo F; Zhang Y; Yu R; Liu Y; Su Z Biomacromolecules; 2018 Mar; 19(3):773-781. PubMed ID: 29328653 [TBL] [Abstract][Full Text] [Related]
20. In vivo Targeting of Liver Cancer with Tissue- and Nuclei-Specific Mesoporous Silica Nanoparticle-Based Nanocarriers in mice. Ding Z; Wang D; Shi W; Yang X; Duan S; Mo F; Hou X; Liu A; Lu X Int J Nanomedicine; 2020; 15():8383-8400. PubMed ID: 33149582 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]